Health Care [ 4/12 ] | Biotechnology [ 32/74 ]
NASDAQ | Common Stock
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.
The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.
Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | -0.16 Increased by +88.81% | -0.72 Increased by +77.78% |
| Jul 31, 24 | -0.59 Increased by +54.62% | -0.77 Increased by +23.38% |
| May 14, 24 | -0.10 Increased by +88.24% | -0.87 Increased by +88.51% |
| Mar 27, 24 | -2.18 Decreased by -1.18 K% | -1.14 Decreased by -91.23% |
| Nov 14, 23 | -1.43 Increased by +55.45% | -1.14 Decreased by -25.44% |
| Aug 8, 23 | -1.30 Increased by +75.93% | -1.13 Decreased by -15.04% |
| May 10, 23 | -0.85 Increased by +78.75% | -1.09 Increased by +22.02% |
| Mar 2, 23 | -0.17 Increased by +95.53% | -1.35 Increased by +87.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by -100.00% | -6.40 M Increased by +84.07% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -23.33 M Increased by +35.66% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -3.71 M Increased by +75.15% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 386.00 K Increased by +107.06% | -64.38 M Decreased by -333.49% | Decreased by -16.68 K% Decreased by -3.21 K% |
| Sep 30, 23 | 3.76 M Decreased by -3.32% | -40.14 M Decreased by -90.68% | Decreased by -1.07 K% Decreased by -97.22% |
| Jun 30, 23 | 2.83 M Decreased by -54.86% | -36.26 M Decreased by -3.03% | Decreased by -1.28 K% Decreased by -128.24% |
| Mar 31, 23 | 2.95 M Decreased by -45.97% | -14.92 M Increased by +36.87% | Decreased by -505.21% Decreased by -16.84% |
| Dec 31, 22 | -5.47 M Decreased by -170.07% | 27.57 M Increased by +215.80% | Decreased by -504.39% Decreased by -65.26% |